Treatment of Parkinson's disease should begin with a dopamine agonist
Identifieur interne : 001D20 ( Main/Exploration ); précédent : 001D19; suivant : 001D21Treatment of Parkinson's disease should begin with a dopamine agonist
Auteurs : Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-09.
English descriptors
- KwdEn :
Abstract
The occurrence of side effects with long‐term levodopa therapy, such as fluctuations in motor performance or abnormal movements, led to a search for new antiparkinsonian drugs. Dopamine agonists include ergot derivatives such as bromocriptine, lisuride, pergolide, and cabergoline and other agents which do not possess the ergot structure such as pramipexole and ropinirole. They all are powerful stimulators of the D2 dopamine receptor which probably underlies their therapeutic effects. The clinical consequences of their binding to other dopamine receptor subtypes (D1 or D3) remains unknown. They are usually prescribed in combination with levodopa when late side effects begin to occur. This review summarizes the available pharmacologic and clinical data to support the early use of dopamine agonists in Parkinson's disease. Several strategies can be used, such as monotherapy or “early” or “late” combination with levodopa. Results of recent well‐performed, modern clinical trials show that early use of the new dopamine agonists is able to effectively control the clinical symptoms for more than 3 years thereby offering the possibility of delaying the occurrence of levodopa‐induced late motor side effects.
Url:
DOI: 10.1002/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of Parkinson's disease should begin with a dopamine agonist</title><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5C24508C66C393E003CAAA391F14B8E0D4E0890C</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L</idno><idno type="url">https://api.istex.fr/document/5C24508C66C393E003CAAA391F14B8E0D4E0890C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001F44</idno><idno type="wicri:Area/Main/Curation">001C50</idno><idno type="wicri:Area/Main/Exploration">001D20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of Parkinson's disease should begin with a dopamine agonist</title><author><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, Inserm U 317, Faculté de Médecine, Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Hôpitaux de Toulouse, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, Inserm U 317, Faculté de Médecine, Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Hôpitaux de Toulouse, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de Pharmacologie Médicale et Clinique, Inserm U 317, Faculté de Médecine, Service de Pharmacologie Clinique, Centre Midi‐Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament and Centre d'Investigation Clinique, Hôpitaux de Toulouse, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09">1999-09</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="725">725</biblScope><biblScope unit="page" to="730">730</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">5C24508C66C393E003CAAA391F14B8E0D4E0890C</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L</idno><idno type="ArticleID">MDS1003</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonists</term><term>Bromocriptine</term><term>Cabergoline</term><term>Dopamine</term><term>Early treatment of Parkinson's disease</term><term>Lisuride</term><term>Parkinson's disease</term><term>Pergolide</term><term>Pramipexole</term><term>Ropinirole</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The occurrence of side effects with long‐term levodopa therapy, such as fluctuations in motor performance or abnormal movements, led to a search for new antiparkinsonian drugs. Dopamine agonists include ergot derivatives such as bromocriptine, lisuride, pergolide, and cabergoline and other agents which do not possess the ergot structure such as pramipexole and ropinirole. They all are powerful stimulators of the D2 dopamine receptor which probably underlies their therapeutic effects. The clinical consequences of their binding to other dopamine receptor subtypes (D1 or D3) remains unknown. They are usually prescribed in combination with levodopa when late side effects begin to occur. This review summarizes the available pharmacologic and clinical data to support the early use of dopamine agonists in Parkinson's disease. Several strategies can be used, such as monotherapy or “early” or “late” combination with levodopa. Results of recent well‐performed, modern clinical trials show that early use of the new dopamine agonists is able to effectively control the clinical symptoms for more than 3 years thereby offering the possibility of delaying the occurrence of levodopa‐induced late motor side effects.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li></region><settlement><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean Louis" last="Montastruc">Jean Louis Montastruc</name></noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><name sortKey="Senard, Jean Ichel" sort="Senard, Jean Ichel" uniqKey="Senard J" first="Jean-Michel" last="Senard">Jean-Michel Senard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5C24508C66C393E003CAAA391F14B8E0D4E0890C
|texte= Treatment of Parkinson's disease should begin with a dopamine agonist
}}
| This area was generated with Dilib version V0.6.23. |  |